CNJ.TO  Cangene Cp

Exchange

TSX

Sector

Life Sciences

Industry

Market Cap.

240.3M

Vuru Grade

39.25/100

Current Price

$3.60
0.00 (0.00%)

Growth Price

$4.10
Undervalued by 13.88%

Stability Price

$2.79
Overvalued by 22.48%

Company Metrics

  • 169 P/E
  • 2.08 P/S
  • 1.25 P/B
  • -0.15 EPS
  • 5.09% Cash ROIC
  • 1.68 Cash Ratio
  • 0 / 0% Dividend
  • 255,197.00 Avg. Vol.
  • 66.75M Shares
  • 240.3M Market Cap.

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

From American vein to Canadian vein
Toronto Star - Jul 18, 2014
The company's long-term goal is to open collection sites across Canada, and a fractionation plant here. In Winnipeg, Cangene Corp., which was recently acquired by Emergent BioSolutions, pays for plasma from a small group of specialized donors who have ...
Cangene Corp Announces FDA Approval Of Botulism Antitoxin
Reuters Key Development - Mar 25, 2013